GE’s Genomic Future On its face, General Electric’s $9.5 billion stock purchase of Amersham is about imaging systems. But the […]

GE’s Genomic Future On its face, General Electric’s $9.5 billion stock purchase of Amersham is about imaging systems. But the

Financial Snapshot For September 2003 A Temporary Pause

Medicine’s Big Bottleneck If health care companies and the U.S. government do not tread carefully, concerns about the cost of

Medicine’s Big Bottleneck If health care companies and the U.S. government do not tread carefully, concerns about the cost of

Stem cell bill eyed as lure to biotech firms A redraft may be in its future, but supporters of a

What’s Really Banging Up Biovail? The Canadian drugmaker says a truck accident caused it to lower guidance. Wall Street skeptics

What’s Really Banging Up Biovail? The Canadian drugmaker says a truck accident caused it to lower guidance. Wall Street skeptics

European biotech – surviving the storm To endure a storm, a sailor must frequently tack and adjust the rigging and

Pharma marketing’s changing skills set As the pharmaceutical industry reacts to change there is a race to find high-calibre commercial